Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia

Published:2024-05-17 Issue:7 Volume:103 Page:2463-2473
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Cui Tong,Li Huiyu,Zhou Shiyuan,Li Jing,Zhu Qian,Zhu Wenjuan,Tang Zaixiang,Ma Xiao,Qiu Huiying,Wu Depei,Wu Xiaojin^ORCID

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

The Key Disease Program of Suzhou

National Science and Technology Major Project

Key Technologies Research and Development Program

Priority Academic Program Development of Jiangsu Higher Education Institutions

Jiangsu Provincial Key Medical Center

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05791-z.pdf

Reference34 articles.

1. Choi Y, Lee J-H, Lee K-H et al (2016) Treatment outcomes and prognostic factors of patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 128:4004. https://doi.org/10.1182/blood.V128.22.4004

2. Shimony S, Stahl M, Stone RM (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98:502–526. https://doi.org/10.1002/ajh.26822

3. Chow KU, Boehrer S, Napieralski S et al (2003) In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 44:165–173. https://doi.org/10.1080/1042819021000054670

4. Scheckel CJ, Meyer M, Betcher JA et al (2020) Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after “CLAG-M” vs. “MEC.” Leuk Res 90:106300. https://doi.org/10.1016/j.leukres.2020.106300

5. Gandhi V, Estey E, Keating MJ et al (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256–264